Physician profile
Grace Wu
NPI 1487703161
$3,702.12
in general payments reported to CMS, 2019-2025
27 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $184 · 2022: $283 · 2023: $797 · 2024: $1,219 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,884 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,884.04 |
| Education | $350.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,411.50 | 2021-2025 | Darzalex, Imbruvica, Talvey |
| Novartis Pharmaceuticals Corporation | $213.08 | 2021-2025 | |
| Edwards Lifesciences Corporation | $197.06 | 2025 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $195.34 | 2022-2025 | Keytruda, Lynparza |
| Genentech USA, INC. | $146.11 | 2023-2025 | Venclexta, Polivy, Tecentriq Hybreza |
| Alnylam Pharmaceuticals INC. | $143.71 | 2025 | Onpattro |
| Gilead Sciences, INC. | $125.00 | 2024 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2024 | Dupixent |
| Eisai INC. | $124.01 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $120.21 | 2024 | Tavalisse, Rezlidhia |
| Medtronic, INC. | $113.71 | 2024 | Intellis Adaptivestim, Corevalve Evolut R |
| Takeda Pharmaceuticals U.S.A., INC. | $113.16 | 2022-2023 | Iclusig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.56 | 2021-2024 | Gilotrif |
| Astellas Pharma US INC | $99.99 | 2025 | |
| Abbvie INC. | $91.62 | 2021-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $55.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.23 | 2021-2022 | |
| Sobi, INC | $38.32 | 2023 | |
| Pfizer INC. | $38.01 | 2025 | |
| Aveo Pharmaceuticals, INC. | $33.24 | 2024 | |
| Incyte Corporation | $32.46 | 2021 | |
| Karyopharm Therapeutics INC. | $29.27 | 2025 | Xpovio |
| Immunogen, INC. | $26.21 | 2023 | Elahere |
| Celgene Corporation | $24.82 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.20 | 2022 | |
| Amgen INC. | $16.39 | 2023 | Lumakras |
| Seagen INC. | $15.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.